Table 2

Characteristics of patients with RA according to the DANBIO registry

VariableDescriptionValue
CDAIComposite disease activity score of patient’s and doctor’s global assessment on a visual analogue scale0.0–76.0
Disease durationTime passed from RA diagnosis until the first-time SABYears
Erosive joint diseaseX-rays of hands and feet registered before the first-time SABErosions/no erosions/unavailable
Autoantibody statusACPA and RF registered before SABPositive/negative/unavailable
SmokingSmoking status registered as close to SAB as possiblePrevious/current/never/occasional/ unavailable
csDMARDs
Methotrexate, sulphasalazine, hydroxychloroquine, leflunomideCurrent user: use within 90 days before SAB
Previous user: ever used >90 days prior to SAB
Non-user: Never used
Cumulated exposure: days on the drug (for current users)
Current/previous/non-user and cumulated exposure (days)
bDMARDs
Anti-TNFs, abatacept, secukinumab, IL6 inhibitors, ustekinumab, apremilastCurrent user: use within 90 days before SAB
Previous user: ever used >90 days prior to SAB
Non-user: never used
Cumulated exposure: days on the drug (for current users)
Current/previous/non-user and cumulated exposure (days)
RituximabCurrent user: last dose of rituximab was given within 12 months prior to SAB
Previous user: ever used
Non-user: never used
Cumulated exposure: total dose (both current and previous users)
Current/previous/non-user and cumulated exposure (mg)
tsDMARDs
JAK inhibitorsCurrent user: use within 90 days before SAB
Previous user: ever used more than 90 days prior to SAB
Non-user: never used
Cumulated exposure: days on the drug (for current users)
Current/previous/non-user and cumulated exposure (days)
Glucocorticoids (GCs)*
Oral and injectable (intramuscular and intraarticular) GCsCurrent user: use within 90 days before SAB
Previous user: ever used >90 days prior to SAB
Non-user: never used
Cumulated exposure: will be calculated as prednisolone-equivalent dose for current users as described elsewhere10
Current/previous/non-user and cumulated exposure (mg)
  • *Use of GCs will be identified in both DANBIO and the Register of Medicinal Products Statistics.

  • CDAI, clinical disease activity index; IL6 inhibitors, interleukin-6 inhibitors (tocilizumab, sarilumab); JAK inhibitors, Janus kinase inhibitors (baricitinib, tofacitinib); RA, rheumatoid arthritis; SAB, Staphylococcus aureus bacteremia; anti-TNF, tumor necrosis factor inhibitors (adalimumab, golimumab, etanercept, certolizumab pegol, infliximab); bDMARDs, biologic disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic DMARDS; tsDMARDs, targeted synthetic DMARDs.